Trials / Completed
CompletedNCT01146509
An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis
An Open-Label, Multicenter, One-Year Extension Of The Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this extension study was to evaluate the safety and efficacy of donepezil hydrochloride after extended use in migraine prophylaxis. Efficacy will continue to be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aricept (donepezil hydrochloride) | Donepezil hydrochloride tablet: initial 5 mg/day dose was taken orally, once a day. At Week 4 visit, the dose was increased to 10 mg/day at the discretion of the investigator. |
Timeline
- Start date
- 2003-01-01
- Primary completion
- 2004-04-01
- Completion
- 2007-03-01
- First posted
- 2010-06-17
- Last updated
- 2012-12-10
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01146509. Inclusion in this directory is not an endorsement.